特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の生体防御市場:2020年~2024年

Global Biodefense Market 2020-2024

発行 TechNavio (Infiniti Research Ltd.) 商品コード 938108
出版日 ページ情報 英文 120 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.84円で換算しております。
世界の生体防御市場:2020年~2024年 Global Biodefense Market 2020-2024
出版日: 2020年05月15日 ページ情報: 英文 120 Pages
概要

世界の生物防御市場は、2020年から2024年の予測期間中に8%のCAGRで推移し、32億2,000万米ドルの成長が見込まれています。 市場は、バイオテロの脅威の高まり、研究開発への政府の資金の急増、および最近の感染症の発生によって牽引されています。

当レポートでは、世界の生体防御市場について調査分析し、市場規模および成長率、市場動向、市場促進要因、課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

エグゼクティブサマリー

市場情勢

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 2019年の市場規模
  • 市場の見通し:2019年から2024年の予測

ファイブフォース分析

アプリケーション別市場セグメンテーション

  • 市場セグメンテーション
  • 用途別比較
  • 炭疽菌-市場規模と予測2019-2024
  • 天然痘-市場規模と予測2019-2024
  • ボツリヌス中毒症-市場規模と予測2019-2024
  • その他-市場規模と予測2019-2024
  • アプリケーション別の市場機会

顧客情勢

地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米 -市場規模と予測2019-2024
  • 欧州-市場規模と予測2019-2024
  • アジア-市場規模と予測2019-2024
  • その他の地域-市場規模と予測2019-2024
  • 主要国
  • 地域の市場機会
  • 市場成長要因
  • 市場の課題
  • 市場動向

ベンダー情勢

  • ベンダー情勢
  • 創造的破壊の状況
  • 競合シナリオ

ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Alexeter Technologies LLC
  • Alnylam Pharmaceuticals Inc.
  • Altimmune Inc.
  • ANP Technologies Inc.
  • Bavarian Nordic AS
  • Cleveland BioLabs Inc.
  • Elusys Therapeutics Inc.
  • Emergent BioSolutions Inc.
  • General Dynamics Corp.
  • GlaxoSmithKline Plc

付録

目次
Product Code: IRTNTR43768

Technavio has been monitoring the biodefense market and it is poised to grow by $ 3.22 billion during 2020-2024 progressing at a CAGR of 8% during the forecast period. Our reports on biodefense market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing threat of bioterrorism, rapid increase in government funding in R&D and recent outbreaks of infectious diseases. In addition, growing threat of bioterrorism is anticipated to boost the growth of the market as well.

The biodefense market analysis includes application segment and geographic landscapes

Technavio's ‘biodefense market ’ is segmented as below:

By Application:

  • Anthrax
  • Smallpox
  • Botulism
  • Others

By Geographic Landscape:

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the government initiatives as one of the prime reasons driving the biodefense market growth during the next few years. Also, growing collaborations and M&A and increasing healthcare expenditure will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our biodefense market covers the following areas:

  • Biodefense market sizing
  • Biodefense market forecast
  • Biodefense market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading biodefense market vendors that include Alexeter Technologies LLC, Alnylam Pharmaceuticals Inc., Altimmune Inc., ANP Technologies Inc., Bavarian Nordic AS, Cleveland BioLabs Inc., Elusys Therapeutics Inc., Emergent BioSolutions Inc., General Dynamics Corp., and GlaxoSmithKline Plc. Also, the biodefense market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Application

  • Market segments
  • Comparison by Application
  • Anthrax - Market size and forecast 2019-2024
  • Smallpox - Market size and forecast 2019-2024
  • Botulism - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Application

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption
  • Competitive scenario

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Alexeter Technologies LLC
  • Alnylam Pharmaceuticals Inc.
  • Altimmune Inc.
  • ANP Technologies Inc.
  • Bavarian Nordic AS
  • Cleveland BioLabs Inc.
  • Elusys Therapeutics Inc.
  • Emergent BioSolutions Inc.
  • General Dynamics Corp.
  • GlaxoSmithKline Plc

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Application - Market share 2019-2024 (%)
  • 22: Comparison by Application
  • 23: Anthrax - Market size and forecast 2019-2024 ($ million)
  • 24: Anthrax - Year-over-year growth 2019-2024 (%)
  • 25: Smallpox - Market size and forecast 2019-2024 ($ million)
  • 26: Smallpox - Year-over-year growth 2019-2024 (%)
  • 27: Botulism - Market size and forecast 2019-2024 ($ million)
  • 28: Botulism - Year-over-year growth 2019-2024 (%)
  • 29: Others - Market size and forecast 2019-2024 ($ million)
  • 30: Others - Year-over-year growth 2019-2024 (%)
  • 31: Market opportunity by Application
  • 32: Customer landscape
  • 33: Market share by geography 2019-2024 (%)
  • 34: Geographic comparison
  • 35: North America - Market size and forecast 2019-2024 ($ million)
  • 36: North America - Year-over-year growth 2019-2024 (%)
  • 37: Europe - Market size and forecast 2019-2024 ($ million)
  • 38: Europe - Year-over-year growth 2019-2024 (%)
  • 39: Asia - Market size and forecast 2019-2024 ($ million)
  • 40: Asia - Year-over-year growth 2019-2024 (%)
  • 41: ROW - Market size and forecast 2019-2024 ($ million)
  • 42: ROW - Year-over-year growth 2019-2024 (%)
  • 43: Key leading countries
  • 44: Market opportunity by geography ($ million)
  • 45: Impact of drivers and challenges
  • 46: Vendor landscape
  • 47: Landscape disruption
  • 48: Industry risks
  • 49: Vendors covered
  • 50: Market positioning of vendors
  • 51: Alexeter Technologies LLC - Overview
  • 52: Alexeter Technologies LLC - Product and service
  • 53: Alexeter Technologies LLC - Key offerings
  • 54: Alexeter Technologies LLC - Key customers
  • 55: Alexeter Technologies LLC - Segment focus
  • 56: Alnylam Pharmaceuticals Inc. - Overview
  • 57: Alnylam Pharmaceuticals Inc. - Product and service
  • 58: Alnylam Pharmaceuticals Inc. - Key offerings
  • 59: Alnylam Pharmaceuticals Inc. - Key customers
  • 60: Alnylam Pharmaceuticals Inc. - Segment focus
  • 61: Altimmune Inc. - Overview
  • 62: Altimmune Inc. - Business segments
  • 63: Altimmune Inc. - Key offerings
  • 64: Altimmune Inc. - Key customers
  • 65: Altimmune Inc. - Segment focus
  • 66: ANP Technologies Inc. - Overview
  • 67: ANP Technologies Inc. - Product and service
  • 68: ANP Technologies Inc. - Key offerings
  • 69: ANP Technologies Inc. - Key customers
  • 70: ANP Technologies Inc. - Segment focus
  • 71: Bavarian Nordic AS - Overview
  • 72: Bavarian Nordic AS - Business segments
  • 73: Bavarian Nordic AS - Key offerings
  • 74: Bavarian Nordic AS - Key customers
  • 75: Bavarian Nordic AS - Segment focus
  • 76: Cleveland BioLabs Inc. - Overview
  • 77: Cleveland BioLabs Inc. - Product and service
  • 78: Cleveland BioLabs Inc. - Key offerings
  • 79: Cleveland BioLabs Inc. - Key customers
  • 80: Cleveland BioLabs Inc. - Segment focus
  • 81: Elusys Therapeutics Inc. - Overview
  • 82: Elusys Therapeutics Inc. - Product and service
  • 83: Elusys Therapeutics Inc. - Key offerings
  • 84: Elusys Therapeutics Inc. - Key customers
  • 85: Elusys Therapeutics Inc. - Segment focus
  • 86: Emergent BioSolutions Inc. - Overview
  • 87: Emergent BioSolutions Inc. - Business segments
  • 88: Emergent BioSolutions Inc. - Key offerings
  • 89: Emergent BioSolutions Inc. - Key customers
  • 90: Emergent BioSolutions Inc. - Segment focus
  • 91: General Dynamics Corp. - Overview
  • 92: General Dynamics Corp. - Business segments
  • 93: General Dynamics Corp. - Key offerings
  • 94: General Dynamics Corp. - Key customers
  • 95: General Dynamics Corp. - Segment focus
  • 96: GlaxoSmithKline Plc - Overview
  • 97: GlaxoSmithKline Plc - Business segments
  • 98: GlaxoSmithKline Plc - Key offerings
  • 99: GlaxoSmithKline Plc - Key customers
  • 100: GlaxoSmithKline Plc - Segment focus
  • 101: Currency conversion rates for US$
  • 102: Research Methodology
  • 103: Validation techniques employed for market sizing
  • 104: Information sources
  • 105: List of abbreviations